Compile Data Set for Download or QSAR
Report error Found 123 of affinity data for UniProtKB/TrEMBL: P41587
TargetVasoactive intestinal polypeptide receptor 2(Human)
Bayer Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50200209(CHEMBL219499)
Affinity DataEC50:  0.0870nMAssay Description:Activity at human VPAC2 receptor in CHO cells by measuring cAMP accumulationMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetVasoactive intestinal polypeptide receptor 2(Human)
Bayer Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50200210(Ac-HSDAVFTDQYTRLRKQVAAKKYLQSIKQKRYC | CHEMBL440082)
Affinity DataEC50:  0.600nMAssay Description:Activity at human VPAC2 receptor in CHO cells by measuring cAMP accumulationMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetVasoactive intestinal polypeptide receptor 2(Human)
Bayer Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50445107(CHEMBL3102924)
Affinity DataEC50:  0.100nMAssay Description:Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assayMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetVasoactive intestinal polypeptide receptor 2(Human)
Bayer Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50445108(CHEMBL3102923)
Affinity DataEC50:  1.20nMAssay Description:Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assayMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetVasoactive intestinal polypeptide receptor 2(Human)
Bayer Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50445109(CHEMBL3102922)
Affinity DataEC50:  0.210nMAssay Description:Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assayMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetVasoactive intestinal polypeptide receptor 2(Human)
Bayer Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50445110(CHEMBL3102921)
Affinity DataEC50:  0.380nMAssay Description:Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assayMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetVasoactive intestinal polypeptide receptor 2(Human)
Bayer Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50445111(CHEMBL3102920)
Affinity DataEC50:  6.60nMAssay Description:Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assayMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetVasoactive intestinal polypeptide receptor 2(Human)
Bayer Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50445112(CHEMBL3102919)
Affinity DataEC50:  0.140nMAssay Description:Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assayMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetVasoactive intestinal polypeptide receptor 2(Human)
Bayer Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50445113(CHEMBL1981592)
Affinity DataEC50:  0.190nMAssay Description:Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assayMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetVasoactive intestinal polypeptide receptor 2(Human)
Bayer Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50445114(CHEMBL3105020)
Affinity DataEC50:  0.390nMAssay Description:Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assayMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetVasoactive intestinal polypeptide receptor 2(Human)
Bayer Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50445115(CHEMBL3105019)
Affinity DataEC50:  1.5nMAssay Description:Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assayMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetVasoactive intestinal polypeptide receptor 2(Human)
Bayer Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50445116(CHEMBL3102931)
Affinity DataEC50:  0.330nMAssay Description:Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assayMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetVasoactive intestinal polypeptide receptor 2(Human)
Bayer Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50445117(CHEMBL3102930)
Affinity DataEC50:  0.0500nMAssay Description:Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assayMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetVasoactive intestinal polypeptide receptor 2(Human)
Bayer Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50445118(CHEMBL3102929)
Affinity DataEC50:  0.210nMAssay Description:Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assayMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetVasoactive intestinal polypeptide receptor 2(Human)
Bayer Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50445119(CHEMBL3102928)
Affinity DataEC50:  3.80nMAssay Description:Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assayMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetVasoactive intestinal polypeptide receptor 2(Human)
Bayer Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50445120(CHEMBL3102927)
Affinity DataEC50:  1.5nMAssay Description:Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assayMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetVasoactive intestinal polypeptide receptor 2(Human)
Bayer Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50445121(CHEMBL3102926)
Affinity DataEC50:  1.40nMAssay Description:Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assayMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetVasoactive intestinal polypeptide receptor 2(Human)
Bayer Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50445122(CHEMBL3102925)
Affinity DataEC50:  0.110nMAssay Description:Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assayMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetVasoactive intestinal polypeptide receptor 2(Human)
Bayer Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50606527(CHEMBL5220770)
Affinity DataEC50:  0.0600nMAssay Description:Agonist activity at VPAC2 in human SH-SY5Y cells assessed as cAMP accumulation incubated for 60 mins by Eu-cAMP tracer based LANCE ultra cAMP assayMore data for this Ligand-Target Pair
In DepthDetails
PubMed
TargetVasoactive intestinal polypeptide receptor 2(Human)
Bayer Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50435130(CHEMBL1893324)
Affinity DataEC50:  0.0800nMAssay Description:Agonist activity at VPAC2 in human SH-SY5Y cells assessed as cAMP accumulation incubated for 60 mins by Eu-cAMP tracer based LANCE ultra cAMP assayMore data for this Ligand-Target Pair
In DepthDetails
PubMed
TargetVasoactive intestinal polypeptide receptor 2(Human)
Bayer Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50606528(CHEMBL5219662)
Affinity DataIC50: 4.5nMAssay Description:Antagonist activity at VPAC2 in human SH-SY5Y cells assessed as inhibition of PACAP38-induced cAMP accumulation pre-incubated for 30 mins followed by...More data for this Ligand-Target Pair
In DepthDetails
PubMed
TargetVasoactive intestinal polypeptide receptor 2(Human)
Bayer Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50250018(PACAP27 | CHEMBL524852)
Affinity DataIC50: 10nMAssay Description:Displacement of Ac-[125I]-PACAP27 from recombinant human VPAC2 expressed in CHO cells after 90 mins by gamma counting analysisMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetVasoactive intestinal polypeptide receptor 2(Human)
Bayer Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50200209(CHEMBL219499)
Affinity DataIC50: 13nMAssay Description:Displacement of [125I]PACAP27 from human VPAC2 receptor expressed in CHO cellsMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetVasoactive intestinal polypeptide receptor 2(Human)
Bayer Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50250074([Bip6]PACAP27 | CHEMBL507480)
Affinity DataIC50: 23nMAssay Description:Displacement of Ac-[125I]-PACAP27 from recombinant human VPAC2 expressed in CHO cells after 90 mins by gamma counting analysisMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetVasoactive intestinal polypeptide receptor 2(Human)
Bayer Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50200210(Ac-HSDAVFTDQYTRLRKQVAAKKYLQSIKQKRYC | CHEMBL440082)
Affinity DataIC50: 27nMAssay Description:Displacement of [125I]PACAP27 from human VPAC2 receptor expressed in CHO cellsMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetVasoactive intestinal polypeptide receptor 2(Human)
Bayer Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50498951(CHEMBL3736134)
Affinity DataIC50: 36nMAssay Description:Displacement of Ac-[125I]-PACAP27 from recombinant human VPAC2 expressed in CHO cells after 90 mins by gamma counting analysisMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetVasoactive intestinal polypeptide receptor 2(Human)
Bayer Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50498951(CHEMBL3736134)
Affinity DataIC50: 36nMAssay Description:Displacement of Ac-[125I]-PACAP27 from recombinant human VPAC2 expressed in CHO cells after 90 mins by gamma counting analysisMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetVasoactive intestinal polypeptide receptor 2(Human)
Bayer Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50498950(CHEMBL3736230)
Affinity DataIC50: 53nMAssay Description:Displacement of Ac-[125I]-PACAP27 from recombinant human VPAC2 expressed in CHO cells after 90 mins by gamma counting analysisMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetVasoactive intestinal polypeptide receptor 2(Human)
Bayer Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50498950(CHEMBL3736230)
Affinity DataIC50: 54nMAssay Description:Displacement of Ac-[125I]-PACAP27 from recombinant human VPAC2 expressed in CHO cells after 90 mins by gamma counting analysisMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetVasoactive intestinal polypeptide receptor 2(Human)
Bayer Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50393775(CHEMBL2159348)
Affinity DataIC50: 1.70E+3nMAssay Description:Antagonist activity at human VPAC2 expressed in CHO cells assessed as inhibition of glucagon-induced cAMP accumulation preincubated for 30 mins prior...More data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetVasoactive intestinal polypeptide receptor 2(Human)
Bayer Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50393788(CHEMBL2159347)
Affinity DataIC50: 2.60E+3nMAssay Description:Antagonist activity at human VPAC2 expressed in CHO cells assessed as inhibition of glucagon-induced cAMP accumulation preincubated for 30 mins prior...More data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetVasoactive intestinal polypeptide receptor 2(Human)
Bayer Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50393776(CHEMBL2159349)
Affinity DataIC50: 2.60E+3nMAssay Description:Antagonist activity at human VPAC2 expressed in CHO cells assessed as inhibition of glucagon-induced cAMP accumulation preincubated for 30 mins prior...More data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetVasoactive intestinal polypeptide receptor 2(Human)
Bayer Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50360601(CHEMBL1933349 | MK-0893)
Affinity DataIC50: 1.28E+4nMAssay Description:Antagonist activity at human VPAC2 expressed in CHO cells assessed as inhibition of glucagon-induced cAMP accumulation preincubated for 30 mins prior...More data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetVasoactive intestinal polypeptide receptor 2(Human)
Bayer Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM86050(Ac-L-His-L-Ser-L-Asp-L-Ala-L-Val-L-Phe-L-Thr-L-Glu...)
Affinity DataKi:  2.10nMMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetVasoactive intestinal polypeptide receptor 2(Human)
Bayer Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM81828(CAS_37221-79-7 | VIP(4-28) | Vasoactive intestinal...)
Affinity DataKi:  2.10nMMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetVasoactive intestinal polypeptide receptor 2(Human)
Bayer Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM85873(VIP Ala2)
Affinity DataKi:  2.10nMMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails Article
PubMed
TargetVasoactive intestinal polypeptide receptor 2(Human)
Bayer Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM85872(VIP Ala19)
Affinity DataKi:  2.40nMMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetVasoactive intestinal polypeptide receptor 2(Human)
Bayer Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM85872(VIP Ala19)
Affinity DataKi:  2.60nMMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetVasoactive intestinal polypeptide receptor 2(Human)
Bayer Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM85889(VIP Ala8)
Affinity DataKi:  2.70nMMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetVasoactive intestinal polypeptide receptor 2(Human)
Bayer Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM85871(VIP Ala9)
Affinity DataKi:  3.20nMMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetVasoactive intestinal polypeptide receptor 2(Human)
Bayer Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM85873(VIP Ala2)
Affinity DataKi:  3.40nMMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails Article
PubMed
TargetVasoactive intestinal polypeptide receptor 2(Human)
Bayer Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM85873(VIP Ala2)
Affinity DataKi:  3.5nMMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails Article
PubMed
TargetVasoactive intestinal polypeptide receptor 2(Human)
Bayer Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM86050(Ac-L-His-L-Ser-L-Asp-L-Ala-L-Val-L-Phe-L-Thr-L-Glu...)
Affinity DataKi:  3.90nMMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetVasoactive intestinal polypeptide receptor 2(Human)
Bayer Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM85886(VIP Ala24)
Affinity DataKi:  4.10nMMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetVasoactive intestinal polypeptide receptor 2(Human)
Bayer Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM85871(VIP Ala9)
Affinity DataKi:  4.30nMMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetVasoactive intestinal polypeptide receptor 2(Human)
Bayer Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM85889(VIP Ala8)
Affinity DataKi:  4.40nMMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetVasoactive intestinal polypeptide receptor 2(Human)
Bayer Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM85879(VIP Ala16 | VIP Ala6)
Affinity DataKi:  4.70nMMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetVasoactive intestinal polypeptide receptor 2(Human)
Bayer Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM85872(VIP Ala19)
In DepthDetails Article
PubMed
TargetVasoactive intestinal polypeptide receptor 2(Human)
Bayer Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM81828(CAS_37221-79-7 | VIP(4-28) | Vasoactive intestinal...)
Affinity DataKi:  5.30nMMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetVasoactive intestinal polypeptide receptor 2(Human)
Bayer Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM85871(VIP Ala9)
In DepthDetails Article
PubMed
Displayed 1 to 50 (of 123 total ) | Next | Last >>
Jump to: